Trial Profile
An Observational study to evaluate Dimethyl fumarate-induced lymphopenia and its mechanism in patients with multiple sclerosis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 May 2017
Price :
$35
*
At a glance
- Drugs Dimethyl fumarate (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Pharmacodynamics
- 08 May 2017 New trial record
- 28 Apr 2017 Results presented at the 69th Annual Meeting of the American Academy of Neurology